VR Logo

Aprea Therapeutics Inc. (APRE) download report


Healthcare | Biotechnology & Pharma Research

Aprea Therapeutics Inc. (APRE) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways.

IPO Date: 03-Oct-2019

Co-Founder, Chief Exec. Officer, Pres and Director: Dr. Oren Gilad Ph.D.

Co-Founder, Director and Advisor: Dr. Kevin D. Smith

Listing: NASDAQ: APRE

Country: United States

Headquarters: Boston, MA

Website: https://atrinpharma.com

Key Facts

Market cap: $18.13 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-35.40 Mln

Cash: $47.65 Mln

Total Debt: $0.25 Mln

Insider's Holding: 8.85%

Liquidity: Low

52 Week range: $0.62 - 5.89

Shares outstanding: 21,974,300

10 Years Aggregate:

  • CFO: $-135.45 Mln
  • EBITDA: $-37,241.36 Mln
  • Net Profit: $-37,240.25 Mln

Stock Performance

Time Period Aprea Therapeutics (APRE) S&P BSE Sensex* S&P Small-Cap 600*
YTD-73.00-8.62-18.78
1 month-5.49-4.54-8.00
3 months-58.33-10.19-13.65
1 Year-84.121.43-17.19
3 Years--10.146.10
5 Years--11.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Aprea Therapeutics (APRE) S&P Small-Cap 600 S&P BSE Sensex
2021-41.6725.2721.99
2020-89.289.5715.75